Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | IDH1 | O75874 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MYOC | Q99972 | 1/20 | 0.52 |
| ▸ | FPR2 | P25090 | 2/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118553 | 0.87 | NPC1 (0.69) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL4548132 | 0.84 | IDH1 (0.64) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL4112443 | 0.84 | NPC1 (0.71) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL4112362 | 0.84 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4112951 | 0.83 | NPC1 (0.61) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL4122903 | 0.83 | NPC1 (0.71) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL4105335 | 0.82 | NPC1 (0.64) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL19707622 | 0.82 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4117928 | 0.81 | NPC1 (0.77) | RAB9ANPC1IDH1SMN1; SMN2KMT2A | |
| SCHEMBL4126914 | 0.81 | GLA (0.54) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885NPC1 927/4885IDH1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.